Pfizer and Novo Nordisk seem to want Metsera bad. Analysts are wondering, though: is the obesity biotech really worth this much effort?

Clinical research company Fortrea Holdings (NASDAQ:FTRE) announced better-than-expected revenue in Q3 CY2025, with sales up 3.9% year on year to $701.3 million. The company’s full-year revenue ...

The number of customer satisfaction (CSAT) responses for Zifo's LCS service has doubled since 2021, reflecting increased ...

Beyond flavour, iru is a nutritional powerhouse with numerous traditional and scientifically supported health benefits.

Ironically enough, his initial downfall had nothing to do with Daraprim. Soon after he became infamous, federal prosecutors ...

CPR can be brutal and ineffective for people clearly at the end of life, but families often insist on it anyway. How should ...

The group says its vaccine business will recover in the medium term when falling immunisation rates cause a severe public ...

Aurinia alleges that Tidmarsh’s statements were not only inaccurate but also motivated by a personal vendetta against Kevin ...

Businesses have warned it is increasingly difficult to operate following tax rises in the last Budget, alongside higher ...

Biotech company Amgen (NASDAQ:AMGN) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 12.4% year on year to $9.56 billion. The company’s full-year revenue guidance of $36.2 billion ...

Software & Services revenue grows 41% to $305 million Annual recurring revenue grows 41% to $1.3 billion Net loss was $2 million, with non-GAAP net income of $98 million and Adjusted EBITDA of $177 ...

The biotechnology company posted revenue of $159.9 million in the period, also missing Street forecasts. Eight analysts surveyed by Zacks expected $167.6 million. Ultragenyx expects full-year revenue ...